We further urge the concentration of efforts in identifying and implementing adjuvant therapeutic schemes based on diets rich in antioxidants and/or their exogenous supplementation
Potential Cardiovascular Benefits: Some GLP-1 agonists, such as semaglutide, have shown to reduce the risk of major cardiovascular events (e.g., heart attacks, strokes), particularly in patients with type 2 diabetes
This weight loss is attributed to its ability to slow gastric emptying and enhance feelings of fullness, which can lead to reduced caloric intake
In the clinic, setmelanotide had no overall effects on heart rate and blood pressure at the doses tested (82)
The should be no worries about the safety of both injectables because they received their Food and Drug Administration (FDA) approval, which means there are fewer risks of severe adverse reactions
For documentation of usage parameters and a copy of the corresponding local cover article a57775, see Local Cover article